Circle Wealth Management
TXG icon

Circle Wealth Management’s 10x Genomics TXG Stock Holding History

Circle Wealth Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$754K Buy
+8,339
New +$488K 0.01% 176

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $17.4B AUM 41.01% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Quantinno Capital Management
Quantinno Capital Management New York $106B AUM 29.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Circle Wealth Management's TXG Position: Q3 2026 in Review

Circle Wealth Management opened a new position in 10x Genomics (TXG) in Q3 2026: 8,339 shares worth $754K. The stake represents 0.01% of the portfolio and ranks #176 among its holdings.

377 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Circle Wealth Management held 8,339 shares of 10x Genomics worth $754K as of Q3 2026.
  • 10x Genomics was a new Circle Wealth Management position in Q3 2026.
  • 10x Genomics made up 0.01% of Circle Wealth Management's portfolio in Q3 2026, its #176 holding.
  • 377 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Circle Wealth Management's 13F filing for Q3 2026, filed 12 Nov 2026.